LEFLUNOMIDE: PHARMACOLOGICAL CHARACTERISTICS (literature review)
https://doi.org/10.51523/2708-6011.2014-11-2-3
Abstract
At present, Leflunomide is a good alternative to Methotrexate in the treatment for rheumatoid arthritis. It can inhibit two enzymes: dihydroorotate dehydrogenase and tyrosine kinase and lead to the development of antiproliferative, antiinflammatory, immunosuppressive and chondroprotective effects.
About the Authors
O. N. Volovikova
Gomel State Medical University
Belarus
Belarus
E. I. Mikhailova
Gomel State Medical University
Belarus
Belarus
G. G. Dundarova
Gomel Regional Clinical Hospital
Belarus
Belarus
E. E. Karpenko
Gomel Municipal Clinical Hospital № 1
Belarus
Belarus
References
1. Alcorn, N. An appraisal of Leflunomide in 10 year after licensing / N. Alcorn, S. Saunders, R. Madhok // Drug Safety. - 2009. - № 32. - P. 1123-1134.
2. Насонов, Е. Л. Перспективы применения лефлуномида в ревматологии / Е. Л. Насонов, Н. В. Чичасова, К. А. Чижова. - M.: РМЖ, 2004. - № 12 (20). - P. 1147-1151.
3. Fox, R. I. Mechanism of action of leflunomide in rheumatoid arthritis / R. J. Fox // J. Rheumatol Suppl. - 1998. - № 53. - P. 20-26.
4. Hormones modulate the effects of leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients / P. Montagna [et al.] // J. Autoimmun. - 2009. - № 32. - P. 254-260.
5. Чичасова, Н. В. Лефлуномид в терапии ревматоидного артрита. Симпозиум «Базисная противовоспалительная терапия ревматических заболеваний» / Н. В. Чичасова, В. Иголкина, Г. Р. Имаметдинова. - М., 2006. - 7 с.
6. De´age, V. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases / V. De´age, D. Burger, J. M. Dayer // Eur. Cytokine Netw. - 1998. - № 9. - P. 663-668.
7. Six months open label trial of leflunomide in active ankylosing spondylitis / H. Haibel [et al.] // Ann. Rheum. Dis. - 2005. - № 64. - P. 124-126.
8. Gupta, R. Risk of hepatotoxicity with add on Leflunomide in a patient / R. Gupta, J. Bhatia, S. K. Gupta // Arzneimettelforschung. - 2011. - № 61. - P. 312-316.
9. Yuyuan, L. Leflunomide-induced acute liver failure: a case report / L. Yuyuan, Z. Xuqing // J. Med. Coll. PLA. - 2010. - № 25. - P. 62-64.
10. Internet website [Электронный ресурс]. - Режим доступа: http:// www.consilium-medicum.com/article/16554. - Дата доступа: 21.01.2014.
11. Internet website [Электронный ресурс]. - Дата доступа: 21.01.2014.
12. Rozman, B. Clinical Pharmacokinetics of Leflunomide / B. Rozman // Clin. Pharmacokinet. - 2002. - № 41. - P. 421-430.
13. Blood Distribution and Single-Dose Pharmacokinetics of Leflunomide / J. Lucien [et al.] // Ther. Drug. Monit. - 1995. - № 17. - P. 454-459.
14. Bredveld, F. C. Leflunomide: Mode of action in the treatment of Rheumatoid Arthritis / F. C. Bredveld, J. Dayer // Ann. Rheum. Dis. - 2000. - № 59. - P. 841-849.
15. Herrmann, M. L. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases / M. L. Herrmann, R. Schleyerbach, B. J. Kirschbaum // Immunopharmacol. - 2000. - № 47. - P. 273-289.
16. Matthias, L. H. Leflunomide in the Treatment of Rheumatoid Arthritis / L. H. Matthias, S. Rudolf, J. K. Bernhard // Clin. Ther. - 2004. - № 26. - P. 447-459.
17. Rezzonico, R. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes / R. Rezzonico, D. Burger, J. M. Dayer // Rheumatology. - 2003. - № 42. - P. 89-96.
18. Brazleton, T. R. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide / T. R. Brazleton, R. E. Morris // Curr. Opin. Immunol. - 1996. - № 8. - P. 710-720.
19. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism / H. M. Cherwinski [et al.] // J. Pharmacol. Exp. Ther. - 1995. - № 272. - P. 460-468.
20. The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical mechanisms / R. T. Elder [et al.] // J. Immunol. - 1997. - № 159. - P. 22-27.
21. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis / R. R. Bartlett [et al.] // Transplant Proc. - 1996. - № 28. - P. 3074-3078.
22. Leflunomide protects from T-cell mediated liver injury in mice through inhibition of nuclear factor kB / M. Imose [et al.] // Hepatology. - 2004. - № 40. - P. 1160-1170.
23. Suppressive effect of leflunomide on Leptin-induced collagen I production involved in hepatic stellate cell proliferation / H. F. Si [et al.] // Exp. Biol. Med. - 2007. - № 232. - P. 427-436.
24. Hoskin, D. W. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction / D. W. Hoskin, R. M. Taylor, A. P. Makrigiannis // Int. J. Immunopharmacol. - 1998. - № 20. - P. 505-513.
25. Waldman, W. J. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide / W. J. Waldman, D. A. Knight, N. S. Lurain // Transplant. - 1999. - № 68. - P. 814-825.
26. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action / Xu. Xiulong [et al.] // Biochem. Pharmacol. - 1999. - № 58. - P. 1404-1413.
27. The active metabolite of Leflunomide, A771726 increases the production of IL-1 receptor antagonist in human synovial fibroblast and articular chondrocytes / G. Palmer [et al.] // Arth. Res. Therapy. - 2004. - № 6. - P. 181-189.
28. Active leflunomide metabolite inhibits interleukin 1b, tumour necrosis factor a, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures / O. Elkayam [et al.] // Ann. Rheum. Dis. - 2003. - № 62. - P. 440-443.
29. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells / P. Baumann [et al.] // Mol. Cancer Ther. - 2009. - № 8. - P. 366-375.
30. Regulation of B cell function by the immunosuppressive agent leflunomide / K. F. Siemasko [et al.] // Transplantation. - 1996. - № 61. - P. 635-642.
Review
For citations:
Volovikova O.N., Mikhailova E.I., Dundarova G.G., Karpenko E.E. LEFLUNOMIDE: PHARMACOLOGICAL CHARACTERISTICS (literature review). Health and Ecology Issues. 2014;(2):18-21. (In Russ.) https://doi.org/10.51523/2708-6011.2014-11-2-3
Views: 245
Email this article 